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I read the article written by Smereka et al. [1] with 
great interest. The authors briefly and accessi-
bly point out the problems of the current SARS-
CoV-2 coronavirus pandemic. One of the main 
symptoms indicated by patients with COVID-19 is 
high fever. Excessive fatigue and muscle pain are 
also indicated [2, 3]. Therefore, one of the key ques-
tions arising in the context of COVID-19 is whether 
and, if so which non-steroidal anti-inflammatory 
drugs to use. 
Opinions on the impact of non-steroidal anti-in-
flammatory drugs on the clinical course of COV-
ID-19 caused by the new SARS-CoV-2 coronavirus 
are divided.
On 11 March 2020, “The Lancet Respiratory 
Medicine” published a publication indirectly ad-
dressing the impact of ibuprofen on the course 
of infection. The coronaviruses of acute respiratory 
syndrome SARS-CoV and SARS-CoV-2 bind to target 
cells by the angiotensin 2-converting enzyme (ACE 
2), which is produced by epithelial cells of the lungs, 
intestines, kidneys and blood vessels. The expression 
of ACE 2 is significantly increased in type 1 or type 
2 diabetic patients who are treated with ACE inhibi-
tors and type II angiotensin receptor blockers (ARB). 
They also are used in the treatment of hypertension, 
which increases the secretion of ACE 2. ACE 2 can 
be increased by ibuprofen, among others. Increased 
expression of this enzyme facilitates COVID-19 in-
fection. Therefore, the hypothesis has been raised 
that the treatment of diabetes and hypertension 
with ACE2 stimulant drugs increases the risk of de-
velopment of severe and fatal COVID-19. ACE2 itself 
is a very important protein. Unfortunately, SARS-
CoV-2 coronavirus binds to it and uses it to enter the 
cells where it multiplies. [4, 5]
According to the European Medicines Agency 
(EMA), there is currently no scientific evidence to con-
firm the link between NSAIDs and the deterioration of 
COVID-19. Healthcare personnel should consider all 
available treatment options, including paracetamol 
and NSAID-19, if a fever occurs in patients with COV-
ID-19. It is recommended that these drugs are used in 
the lowest effective dose and for the shortest possible 
period. There is, therefore, no reason for patients 
taking ibuprofen to discontinue treatment. This is 
particularly important for patients receiving ibuprofen 
or NSAIDs due to chronic diseases [6].
On 19 March 2020, the World Health Organisa-
tion (WHO) issued an official statement in which it 
stated that the WHO is not against the use of ibu-
profen based on existing data. However, it is aware 
of concerns about its use in the treatment of fever 
in people with COVID-19. It has been informed that 
physicians are being consulted and that it has not 
been informed of any negative effects beyond the 
usual side effects that limit the use of ibuprofen in 
some cases [7].
To summarize, there are no studies confirming 
higher mortality of COVID-19 when ibuprofen is 
used in the treatment. However, in doubtful cases, 
the use of paracetamol instead of ibuprofen is rec-
ommended but this refers only to its use without 
a physician’s prescription [8].
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